MRK

European Commission Approves KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as First PD-1 Inhibitor Plus Antibody-Drug Conjugate Regimen for Adults With Cisplatin-Ineligible Resectable Muscle-Invasive Bladder Cancer

EXEL Down on Colorectal Cancer Study Data on Zanzalintinib

Merck's Anti-TL1A Antibody Meets Goal in Ulcerative Colitis Study

Merck and Mae Partner to Expand Doula Workforce and Address Maternal Health Disparities in High-Risk U.S. Markets

AbbVie and Merck Face-Off: Which Pharma Stock Has the Lead?

Merck's Oncology Engine Is Still Accelerating

Merck's bowel disease drug meets main goal in late-stage trial